FY23 ANNUAL REPORT
ORSERDU approved by the FDA
A new breast cancer therapeutic developed at Duke has received FDA approval and is going to the market.
Isolere Bio acquired by Donaldson
A Duke professor and graduate student built the company around their phase-separating purification technology.
Tellus Therapeutics raises a $35M Series A round
Neonatal care company commercializing breast milk-based therapies based on Duke research is thriving.
15
This year, we helped launch a variety of start-ups with offerings from smart toilets to 4D mammography.
$1M+ awarded through Gilhuly Accelerator Fund
OTC’s new translational fund has been deployed to support 14 Duke research projects with commercial potential.
Triangle Venture Day gathers steam
Duke New Ventures and counterparts at UNC, NC State, and the NC Biotech Center are growing this regular event into a Southeastern VC staple.
Faculty donates back to OTC
Professor Jungsang Kim and his wife Soyeon Nam gave $1M to OTC to help fellow entrepreneurial Duke inventors.
Translation & Commercialization as a collaborative, creative process
OTC licensing managers are creative partners to Duke inventors – just ask pathologist Dr. Soman Abraham and OTC’s Dr. Dennis Thomas.
Four Points Innovation funds its first project
Therapeutics development partnership with investment firm Deerfield Management is sprouting commitments.